The memory of mice with Alzheimer's greatly improved after they were injected with two newly discovered short peptides.
List view / Grid view
Filter the results
Currently, there is no licensed treatment to slow or stop the progression of Parkinson’s disease. However, a team at Sheffield University in the UK are currently working to identify compounds that target the dopaminergic brain cells affected by the disease. Nikki Withers speaks to Dr Heather Mortiboys to hear how…
Aparajita Dubey summarises the recent trends in upstream bioprocessing and highlights the challenges and solutions involved in its process development.
Chronic inflammatory processes in ageing brains lead to lymphoma cells that have entered the brain tissue being retained.
New research findings suggest that gut microbiota may regulate lupus flares in pregnant women, presenting a therapeutic target.
A new drug discovery strategy predicts the clinical actions of new compounds to promote desired clinical responses and avoid side effects.
It is predicted that there will be 70 new monoclonal antibody (mAb) biotherapeutics available by 2020.
New lab on a chip technology has been developed to evaluate the effects of different drivers of NAFLD on liver cells.
Targeting a deadly bacteria's use of succinate in the lungs could control infection and improve the health of people with cystic fibrosis.
TSKgel FcR-IIIA-NPR is based on a recombinant FcγIIIa receptor ligand immobilized on a non-porous polymer particle. It allows fast assessment of biologic activity of monoclonal antibodies.
Libraries of more than 9,000 macrocyclic molecules below 1 KDa have been generated, small enough to cross cell membranes and reach targets.
A pharmaceutical target has been identified by Duke University that, when activated, can reverse bone degradation caused by osteoporosis.
A new drug target for treating glioblastoma has been identified from a cellular pathway found to contribute to the spread of glioma stem cells.